Pazopanib, brand name Votrient, is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), and KIT. Inhibitors of VEGFR like pazopanib (Votrient, GlaxoSmithKline), show activity against leiomyosarcoma, synovial sarcoma and other sarcomas including those of vascular origin. There is one supportive phase II study from EORTC. It concluded: “Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.”
Pazopanib is being investigated in a large randomized placebo-controlled phase III study, which has recently completed accrual and has survival as its endpoint. Pazopanib is in a large randomized placebo-controlled phase III study, which has recently completed accrual and has survival as its endpoint. This study was presented at ASCO 2011. It was for metastatic disease, not adjuvant, and it found that Pazopanib is an active drug in anthracycline pretreated metastatic Soft Tissue Sarcoma pts with an increase in median PFS of 13 weeks.
On April 26, 2012, the FDA approved pazopanib hydrochloride tablets (Votrient®, made by GlaxoSmithKline) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The efficacy of pazopanib hydrochloride for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors (GIST) has not been demonstrated.
Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L. et al. (2009). “Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)”. Journal of Clinical Oncology 27 (19): 3126
For liposarcoma: Results of a prospective, single-arm, multicentre, phase 2 trial suggest that pazopanib might have activity in patients with unresectable or metastatic liposarcoma, a rare malignancy with poor prognosis, but it needs to be confirmed.
Lancet Online 2017 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30663-0/fulltext